SOHU [SOHU COM] 8-K: (Original Filing)
[]
TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)
[TPI Reports First Quarter Fiscal Year 2013 Financial Results CHENGDU, China, Nov. 15, 2012 -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for first quarter of the fiscal year 2013. First Quarter of Fiscal Year 2013 Ended] [Tianyin Pharmaceutical Co., Inc. (“TPI”) First Quarter of Fiscal Year 2013 Earnings Call November 15, 2012 8:30 AM ET Operator James Tong TPI First quarter of fiscal year 2013 ended September 30, 2012, financial highlights: revenue was $16 million compared with $17.5 million in first quarter of fiscal year 2012 (“FIQ 2012”). Operating income was $2.2 million compared with $2.1] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 15, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Reports First Quarter Fiscal Year 2013 Financial
[TPI Reports First Quarter Fiscal Year 2013 Financial Results CHENGDU, China, Nov. 15, 2012 -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for first quarter of the fiscal year 2013. First Quarter of Fiscal Year 2013 Ended] [Tianyin Pharmaceutical Co., Inc. (“TPI”) First Quarter of Fiscal Year 2013 Earnings Call November 15, 2012 8:30 AM ET Operator James Tong TPI First quarter of fiscal year 2013 ended September 30, 2012, financial highlights: revenue was $16 million compared with $17.5 million in first quarter of fiscal year 2012 (“FIQ 2012”). Operating income was $2.2 million compared with $2.1] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 15, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
CBAK [CHINA BAK BATTERY] 8-K: PRESS RELEASE China BAK Announces Appointment of New
[PRESS RELEASE China BAK Announces Appointment of New Independent Director Shenzhen, China November 21, 2012 Dr. Agee is a financial and legal expert with extensive business experience. She is a frequent speaker on a broad range of business and legal topics. Dr. Agee is currently a senior lecturer of business law at Hankamer School of Business of Baylor University]
CBPO [China Biologic Products] 8-K: (Original Filing)
[CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND PRIVILEGES ____________________________________________________________ 1. He is the duly elected and acting Chief Executive Officer of China Biologic Products, Inc., a Delaware corporation (the Corporation ). Board Preferred Stock ), of the Corporation designated as Series A Participating Preferred Stock: RESOLVED Charter ), the Board does hereby provide for the issuance of a series] [PREFERRED SHARES RIGHTS AGREEMENT Dated as of November 20, 2012 CHINA BIOLOGIC PRODUCTS, INC. and SECURITIES TRANSFER CORPORATION as Rights Agent TABLE OF CONTENTS Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 9 Section 3. Issuance of Rights Certificates 9 Section 4. Form of Rights Certificates 11 12 Section 6. Transfer, Split Up, Combination and Exchange] [CHINA BIOLOGIC PRODUCTS, INC. ADOPTS STOCKHOLDER RIGHTS PLAN The stockholder rights plan, which has a term of two years, is designed to guard against partial tender offers and other coercive tactics to gain control or undue influence of China Biologic without offering a fair and adequate price and terms to China Biologics stockholders. The plan does not prevent China Biologics] [FORM 8-K Current Report Date of Report (Date of earliest event reported): CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction (I.R.S. Employer Identification No.) 18th Floor, Jialong International Building 19 Chaoyang Park Road 86-10-6698-3166 (Former name or address, if changed since last report) Item 1.01. Entry into a Material Definitive Agreement. On November 19, 2012, the Board]
CNET [ChinaNet Onlines,] 8-K: (Original Filing)
[exh_991.htm 2 EX-99.1]
